CytRx (CYTR) Receives EPO Patent for Linker Platform; Giver 'Aldoxorubucin' Name to INNO-206
Tweet Send to a FriendGet Alerts CYTR Hot Sheet
Up)
Trade CYTR Now!
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company’s tumor-targeting linker platform technology and pharmaceutical compositions.
CytRx also unveiled aldoxorubucin as the new generic name for INNO-206, the conjugate comprised of the protein-binding linker technology and the commonly prescribed chemotherapeutic drug doxorubicin.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
CytRx also unveiled aldoxorubucin as the new generic name for INNO-206, the conjugate comprised of the protein-binding linker technology and the commonly prescribed chemotherapeutic drug doxorubicin.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Santarus (SNTS) to Present Additional Data on UCERIS
- Maxwell Tech (MXWL) Recieves NASDAQ Notification Letter, Expects to Satisfy Conditions
- James River Coal (JRCC) Higher; Announces Private Exchange Pacts on Notes
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
